Home / Clinical Trial / FASTRACK II

Current Clinical Trials

FASTRACK II

 Kidney — In Follow-up

Surgery is the standard treatment for primary kidney cancer. However, in some cases, surgery is either not possible or other health problems make surgery high risk. This study involves a relatively new, highly precise multidirectional radiotherapy technique called Stereotactic Ablative Body Radiotherapy (SABR) which will be applied to all participants.

The aim of the study is to test the ability of the technique to control cancer within the kidney for those people for whom surgery is not an option, and to examine the side effects of the treatment, including how it may affect your kidney’s function.

This study is led by TROG and co-badged by ANZUP Cancer Trials Group and is now closed to recruitment and is in follow up.

If you think this trial might be right for you, please ask your doctor.

TRIAL TITLE

TROG 15.03 Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney – A Phase II Clinical Trial

CONSUMER TITLE

Study testing whether a highly targeted form of radiation therapy (SABR) can safely control kidney cancer in people who are not able to have surgery.

CANCER TYPE

Kidney

TRIAL STATUS

In Follow-up

PROTOCOL NUMBER

TROG 15.03

CO-ORDINATING CENTRE

STUDY CHAIR

Prof Shankar Siva

PATIENT POPULATION

Renal cell carcinoma (RCC)

RECRUITMENT TARGET

70 participants

ACKNOWLEDGEMENT

COLLABORATORS

DETAILED INFORMATION

ANZCTR

LATEST PUBLICATION

PARTICIPATING CENTRES